Assignment of patients diagnosed with acute myeloid leukemia(AML)to the 2022 European LeukemiaNet(ELN)favorable genetic risk group has important clinical implications,as allogeneic stem cell transplantation in first c...Assignment of patients diagnosed with acute myeloid leukemia(AML)to the 2022 European LeukemiaNet(ELN)favorable genetic risk group has important clinical implications,as allogeneic stem cell transplantation in first complete remission(CR)is not advised due to a relatively good outcome of patients receiving chemotherapy alone and transplant-associated mortality.However,not all favorable genetic risk patients experience long-term relapse-free survival(RFS),making recognition of patients who would most likely be cured of high importance.展开更多
基金supported by the National Library of Medicine of the National Institutes of Health under award R01LM013879Research reported in this publication was also supported in part by the National Cancer Institute at the National Institutes of Health under award R01CA262496,R01CA284595,R01CA283574,U10CA180821,U10CA180882,U24CA196171,UG1CA233327,UG1CA233331,UG1CA233338,UG1CA 233339,R35CA197734,and P30CA016058+4 种基金the Coleman Leukemia Research Foundationan ASH Junior Faculty Scholar Award and ASH Bridge Grant(to A.-K.E.)the Leukemia Research Foundation(to A.-K.E.)the Leukemia&Lymphoma Society(to A.-K.E.)The D.Warren Brown Foundation。
文摘Assignment of patients diagnosed with acute myeloid leukemia(AML)to the 2022 European LeukemiaNet(ELN)favorable genetic risk group has important clinical implications,as allogeneic stem cell transplantation in first complete remission(CR)is not advised due to a relatively good outcome of patients receiving chemotherapy alone and transplant-associated mortality.However,not all favorable genetic risk patients experience long-term relapse-free survival(RFS),making recognition of patients who would most likely be cured of high importance.
